Stockreport

ImmunityBio: Making Strides, But Beware The Hype (Rating Downgrade) [Seeking Alpha]

ImmunityBio, Inc.  (IBRX) 
PDF ImmunityBio's Anktiva is approved for NMIBC and expanding globally, with key clinical catalysts in 2026 and promising signals in NSCLC and cell therapy. Despite 700% [Read more]